Strategic design of drug core structure - from natural molecules to non-natural molecules

We have been engaged in the design, synthesis and evaluation of biologically active molecules. We have synthesized numerous molecules of various structure with miscellaneous activity. Now I describe what we have done from the strategic viewpoint.
 
1.     From Natural Bleomycin to Non-Natural Bleomycin
1.1   What is Bleomycin
1.2   How we designed Non-Natural Bleomycin
1.3   Simplification of Bleomycin Structure
1.4   Symmetrization of the Metal Core
1.5   New Function: Zinc Protein Inhibition
1.5.1. Zinc Finger Protein
1.5.2. Farnesyltransferase
1.5.3. HIV-1 Vif vs Host Protein APOBEC3G
1.6. Application to Chronic Inflammation
1.6.1. Cancer Metastasis
1.6.2. Crohn’s Disease
1.6.3. Systemic Sclerosis
 
2.     From Natural Inositol Phospholipids to Non-Natural Inositol Phospholipids
2.1. Biotinylated Inositol Phosphate
2.2. PLCd PH Domain Interaction
2.3. HIV and Inositol Phospholipid
2.4. Towards the Eradication of AIDS
 
Bio:
Prof. Masami Otsuka got his Ph.D from University of Tokyo in 1983. He did a postdoctoral research fellow at Oxford University in the group led by Professor Jack E. Baldwin. From 1997, he started his professorship in the Faculty of Pharmaceutical Sciences in Kumamoto University, and headed the School of Pharmacy, Graduate School of Pharmaceutical Sciences between 2011-2014. Since 2013, Prof. Otsuka serves as the vice president of the Pharmaceutical Society of Japan.
 
His current research themes focus on synthetic study of biofunctional artificial compounds and natural products,  and molecular virological study of HIV.